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Low Serum Hepcidin Is Associated With 
Reduced Short-Term Survival in Adults 
With Acute Liver Failure
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Robert J. Fontana,4 Pavel Strnad,1 and for the Acute Liver Failure Study Group (ALFSG)
The liver has an important role in iron homeostasis through the synthesis of the serum transporter transferrin and 
the iron hormone hepcidin. The aim of this study was to analyze parameters of iron metabolism in a multicenter 
cohort of adult patients with acute liver failure (ALF) and in an acetaminophen (APAP)-induced ALF mouse 
model. A representative subset of 121 adults with ALF (including 66 APAP-related patients) had baseline serum 
samples tested for ferritin, transferrin, iron, and hepcidin. Outcomes at 3 weeks after enrollment were categorized as 
spontaneous survivor (SS) versus death/transplantation (NSS). Mice were assessed before (controls) and 4 and 18 
hours after injection of 300 mg/kg APAP. Patients with ALF as well as APAP-treated mice displayed increased 
ferritin and diminished serum hepcidin and hepcidin/ferritin ratio. SS had lower iron (29.1% vs. 34.5 µmol/L; 
P  < 0.05) and transferrin saturation (60.9% vs. 79.1%; P  < 0.01), but higher hepcidin levels (8.2 vs. 2.7 ng/mL; 
P  < 0.001) and hepcidin/ferritin ratio (0.0047 vs. 0.0009; P  < 0.001) than NSS. In a multivariate analysis, a 
log-transformed hepcidin-containing model displayed similar prognostic power as the established Acute Liver Failure 
Study Group index (C-statistic 0.87 vs. 0.85) and was better than Model for End-Stage Liver Disease score 
(C-statistic 0.76). In mice, hepcidin levels inversely correlated with the surrogate of liver injury. Conclusion:  Our 
findings demonstrate that several serum iron parameters significantly associate with 3-week outcomes in adults with 
ALF. Among them, hepcidin decreases early during experimental APAP-induced ALF, is an independent predictor 
and might be a useful component of future prognostic scores. (Hepatology 2019;69:2136-2149).
Acute liver failure (ALF) is an uncommon condition characterized by a rapid loss of liver function in individuals without a 
pre-existing liver disease.(1) In the United States, 
nearly 50% of ALF cases are due to acetaminophen 
(APAP) overdose, whereas idiosyncratic drug-in-
duced liver injury and indeterminate ALF are the 
most common causes of non-APAP-related ALF 
and associated with a high rate of short-term mor-
tality.(1) Although liver transplantation is an effec-
tive therapy in selected patients, the decision for/
against transplantation is challenging because of 
the fast pace of disease development, lack of donor 
organs, and a resulting need for life-long immu-
nosuppressive therapy.(2-4) To facilitate this deci-
sion, multiple prognostic markers/scores have been 
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developed. The Model for End-Stage Liver Disease 
(MELD) and King´s College Criteria are both com-
monly used prognostic models.(3-5) In addition, the 
U.S. Acute Liver Failure Study Group (ALFSG) 
index is a useful prognostic tool(6) that includes the 
clinical/demographic parameters of ALF etiology, 
the need for vasopressor use, grade of encephalop-
athy, and liver-related laboratory values of bilirubin 
and international normalized ratio (INR).(3,7) Given 
that the currently available scores have only a lim-
ited ability to detect a potentially lethal ALF, there 
is a constant search for novel predictors.(8-10)
Iron is an essential, but potentially toxic, element 
that causes oxidative stress and promotes the devel-
opment of bacterial infections.(11-13) Iron is physio-
logically sequestered as transferrin in the serum and 
ferritin in the parenchymal cells.(14) Hepatocytes con-
stitute the major parenchymal iron storage pool and 
contain large amounts of ferritin. A small fraction of 
ferritin is released into the serum. In the absence of 
liver injury, serum ferritin is used as a surrogate for 
the parenchymal iron load.(13-15) The ratio of serum 
iron and transferrin is termed transferrin saturation 
(TSAT), indicating the amount of serum iron load.(14) 
Iron metabolism is regulated by hepcidin, a hormone 
produced primarily in the hepatocytes that blocks 
the uptake of iron in the intestine and release of iron 
from macrophages.(13,15) Hepcidin is a short-living 
hormone (serum half-life of several minutes)(16) and is 
subjected to a complex regulation with hypoxia, ane-
mia, and iron deficiency being the major suppressors 
whereas inflammation and iron overload are the major 
inducers.(17)
Multiple studies demonstrated that parameters of 
iron metabolism represent useful predictors of liver 
disease outcome. For example, decreased transfer-
rin and elevated TSAT associated with an adverse 
outcome in patients with liver cirrhosis, ALF, and 
acute-on-chronic liver failure.(11,18-20) In contrast, 
increased ferritin indicated a life-threatening disease 
in some, but not all, analyses.(11,18,19,21) In studies 
that measured hepcidin levels, decreased serum hep-
cidin associated with a poor survival in patients with 
alcoholic liver cirrhosis.(22) In acute-on-chronic liver 
failure, the association between low hepcidin and 
increased mortality was seen in one, but not the other, 
report.(18,19) Given these data, we aimed to analyze the 
changes in iron metabolism occurring in ALF and to 
delineate their prognostic usefulness. For this purpose, 
we assessed a mouse model of acetaminophen-related 
ALF and also investigated iron parameters in a mul-
ticenter U.S. ALF cohort that were prospectively fol-
lowed for 3-week outcomes.
Patients and Methods
aNIMal eXpeRIMeNtS
Ten-to-twelve-week-old wild-type C57BL/6N 
mice were kept under standardized conditions (12-
hour day/night cycle, 20°C-24°C, humidity 50%). 
In the APAP-induced acute liver injury model, mice 
were fasted for 12 hours before an intraperitoneal 
injection of 300 mg APAP/kg body weight (Sigma-
Aldrich, St. Louis, MO) and received free access to 
food and water thereafter.(23) The animals were sac-
rificed 4 or 18 hours after APAP administration by 
cervical dislocation after an inhalational anesthe-
sia with isoflurane (AbbVie AG, Ludwigshafen, 
Germany). Control mice of the same age, sex, and 
genetic background received no treatment. Blood 
was collected through a cardiac puncture, and serum 
was obtained through centrifugation for 15 minutes 
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at 2,000g . Levels of serum aminotransferases were 
measured in the Clinical Chemistry Department 
of Aachen University Hospital. Levels of hepcidin 
(LSBio LS-F5905; LifeSpan Biosciences, Seattle, 
WA), ferritin (ab157713; Abcam, Cambridge, United 
Kingdom), and transferrin (ab157724; Abcam) were 
measured by commercially available enzyme-linked 
immunosorbent assay (ELISA) kits as recommended 
by the suppliers. RNA isolation and complementary 
DNA preparation were performed with the RNeasy 
mini kit (Qiagen, Hilden, Germany) and Superscript 
II reverse transcriptase (Invitrogen, Darmstadt, 
Germany), respectively. Quantitative PCR was car-
ried out with a 7500 fast Real-Time PCR Sequence 
Detection System (Applied Biosystems, Foster City, 
CA). The specific primers are listed in Supporting 
Table S1. The relative expression levels of mRNA 
were determined with the help of ddct method and 
the ribosomal RNA gene L7 was employed as internal 
control.
Livers were removed, cut, and placed in 10% 
buffered formaldehyde overnight. After that, they 
were dehydrated, embedded in paraffin, and cut into 
3-µm-thick sections. To study the overall tissue archi-
tecture, the specimens were stained with hematoxy-
lin and eosin (H&E). Images were obtained with a 
Leica light microscope (Leica, Solms, Germany) 
equipped with a digital camera and Leica Application 
Suite software V4.1 (Leica Microsystems, Heerbrugg, 
Switzerland). The animal experiments were approved 
by the responsible Institutional Animal Care 
Committee.
patIeNtS
The analyzed cohort was randomly selected from 
a pool of 2,244 adult patients that were prospec-
tively identified and recruited at 31 tertiary U.S. 
centers participating in the ALFSG.(1) All subjects 
met the ALF criteria, i.e., presence of coagulopathy 
(international normalized ratio ≥ 1.5) and hepatic 
encephalopathy occurring within 26 weeks of the 
first symptoms in individuals without a pre-existing 
liver disease.(1) The selection of patient samples 
was carried out by the ALFSG staff not involved 
in the analysis of obtained results. The institutional 
review boards of all participating centers approved 
the research, and the clinical investigation has been 
conducted according to the principles expressed in 
the 1975 Declaration of Helsinki. As the patients 
enrolled had by definition an altered mental sta-
tus, written informed consent was obtained from 
the legal next of kin. Monitoring and therapeu-
tic interventions were implemented by each cen-
ter according to institutional standards of care. 
Demographic, clinical, laboratory, radiologic, and 
21-day transplant-free outcomes data were recorded 
prospectively.
laBoRatoRy paRaMeteRS
The measurements of ferritin (electrochemilumi-
nescence; Elecsys ferritin, cat. nr. 04491785 190), 
transferrin (turbidimetry; Tina-quant Transferrin 
ver.2), and serum iron (photometry; Iron Gen.2) were 
performed by the Clinical Chemistry Department of 
Aachen University Hospital using the Cobas 8000 
system (Roche Diagnostics, Mannheim, Germany). 
The reference ranges were as follows: serum iron 
5.8-35 µmol/L; transferrin 200-360 mg/dL; TSAT 
25%-45%; ferritin 13-150 ng/mL (males), 30-400 
ng/mL (females). For the determination of serum 
hepcidin concentrations, a commercially available 
ELISA kit was used (EIA-5782; DRG Instruments, 
Marburg, Germany).(19,22,24) Measurements of fer-
ritin, transferrin, iron, and hepcidin provided valid 
results in 120 (99%), 121 (100%), 121 (100%), and 
113 (93%) patients, respectively. All analyzed sam-
ples were obtained from the first two visits after the 
inclusion of the patient into the study (i.e., day one 
or two).
StatIStICal aNalySIS
Continuous variables were presented as the 
mean ± standard deviation and compared using the 
Student t test, whereas continuous nonparamet-
ric variables were displayed as median (interquartile 
range) and compared with the Wilcoxon rank-sum 
test. Categorical variables were presented as num-
ber (percentage), and comparison for proportion was 
done using the chi-squared test or Fisher’s exact test. 
Spearman’s correlation coefficient was used to analyze 
correlations between variables.
The study of associations with transplant-free sur-
vival at 21 days after study enrollment was done using 
a univariate logistic regression model, and all the clin-
ically relevant covariates with P  < 0.2 were chosen for 
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a stepwise multivariable logistic regression model. All 
continuous variables were assessed and the appropri-
ate transformations were done as necessary. All con-
tinuous variables were also analyzed for colinearity. 
The final multivariable model was assessed using the 
area under the receiver operating characteristic curve 
(AUROC) or concordance c-statistic—a measure of 
discriminatory ability. The performance of the final 
model was compared with two other spontaneous sur-
vivor (SS) prediction models based on outcome indi-
ces, namely MELD and ALFSG Prognostic Index, 
using AUROC.
Statistical significance was defined as a two-sided 
P value <0.05. Statistical analyses were performed 
using SAS software, version 9.4 (SAS Institute Inc., 
Cary, NC) and RStudio: Integrated Development 
Environment for R, version 1.1.383 (Rstudio Inc., 
Boston, MA).
Results
apap-INDUCeD aCUte lIVeR 
INJURy IN MICe ReSUltS 
IN alteReD SeRUM IRoN 
paRaMeteRS
The impact of experimental ALF on parameters of 
iron metabolism was studied in mice subjected to APAP 
overdose. Eighteen hours after APAP administration, 
we observed a marked increase in serum aspartate 
aminotransferase (AST) and alanine aminotransferase 
(ALT) levels (Supporting Table S2) and the appearance 
of characteristic centrilobular necrosis in H&E stain-
ing (Fig. 1A). Moreover, elevated levels of acute phase 
response and inflammatory marker genes were noted 
(Supporting Fig. S1). Although APAP treatment for 
18 hours did not result in obvious changes in transfer-
rin (Fig. 1C), it led to significantly elevated serum iron 
(38.5 ± 26.1 vs. 28 ± 6.8 µmol/L; P  < 0.01; Fig. 1B) and 
ferritin (18,830 ± 33,987 vs. 871 ± 384 g/L; P  < 0.001; 
Fig. 1D) and diminished hepcidin levels (25.5 ± 15.3 
vs. 53.3 ± 24.4 ng/mL; P  < 0.01; Fig. 1E). Interestingly, 
hepcidin levels in APAP-treated mice negatively cor-
related with ALT (r = −0.72; P  < 0.01) and AST 
(r = −0.62; P  < 0.05). On the other hand, a significant 
positive correlation with ALT and AST was seen for 
ferritin (ALT: r = 0.91; AST: r = 0.84; P  < 0.0001 for 
both; Supporting Table S3). These results suggest that 
serum ferritin reflects the hepatocellular injury whereas 
serum hepcidin may mirror the resulting decrease in the 
synthetic capacity of the liver. In line with this hypothe-
sis, the hepatic mRNA levels of ferritin, transferrin, and 
hepcidin did not differ significantly between control ani-
mals and mice exposed with APAP for 18 hours, thereby 
demonstrating that the observed serum alterations are 
not due to transcriptional changes (Supporting Fig. S2).
To test whether the observed changes in serum 
iron, ferritin, and hepcidin levels occur early after 
APAP-induced injury, we analyzed mice exposed with 
APAP for 4 hours. Even at this early time point, the 
animals displayed a marked elevation in serum AST, 
ALT, and ferritin levels as well as decreased serum 
hepcidin values (Supporting Table S4; Supporting 
Fig. S3). On the other hand, serum iron levels did not 
differ significantly between the untreated and APAP-
exposed animals (Supporting Fig. S3).
CHaRaCteRIStICS oF tHe alF 
patIeNt CoHoRt
To determine the role of iron parameters in 
human ALF, we analyzed serum samples at the time 
of enrollment in 121 patients with ALF randomly 
selected from the prospective multicenter U.S. 
ALFSG registry (Fig. 2). Our subcohort was rep-
resentative of the entire registry (Supporting  Table 
S5) and consisted of 66 APAP and 55 non-APAP 
cases (Fig. 2). In the non-APAP group, autoimmune 
hepatitis, idiosyncratic drug-induced liver injury, 
and hepatitis B were the most common etiologies 
(Supporting Fig. S4). At day 21 after enrollment, 
59 subjects (48.8%) were classified as SS, whereas 
30 subjects (24.8%) died and 32 subjects (26.4%) 
received a liver transplant. The latter two catego-
ries were analyzed together and labeled as non-SS 
(NSS). In line with previous data,(1) spontaneous 
survival tended to be more frequent in APAP-
versus non-APAP-induced ALF (57.6% vs. 38.2%; 
P = 0.05; Fig. 2). Moreover, individuals with APAP 
etiology were younger and had higher transaminases 
and higher grades of hepatic encephalopathy, when 
both admission and peak levels were considered. In 
contrast, non-APAP ALF cases had higher bilirubin 
and alkaline phosphatase values and less frequently 
needed ventilator therapy (Table 1).
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Next, we investigated factors associated with spon-
taneous survival at day 21. As reported,(1) females 
were more likely to display spontaneous survival 
(84.7% in SS vs. 64.5% in NSS; P  < 0.05), and SS had 
lower bilirubin, INR, and MELD scores, when both 
admission and peak values were considered (Table 2). 
In contrast, NSS had lower platelet counts and higher 
grades of hepatic encephalopathy and more frequently 
needed vasopressor therapy and ventilator support 
(Table 2).
IRoN paRaMeteRS aRe 
alteReD IN alF aND DIFFeR 
BetWeeN SpoNtaNeoUS 
SURVIVoRS aND NoN-
SpoNtaNeoUS SURVIVoRS
In patients with ALF, serum iron levels were slightly 
elevated or at the upper limit of normal. ALF individ-
uals also displayed somewhat diminished transferrin 
values and strongly increased TSAT and ferritin levels 
FIg. 1. Acetaminophen-induced liver injury leads to altered parameters of iron metabolism. (A) Hematoxylin and eosin staining 
reveals the liver architecture in nontreated mice (control; a) and animals exposed to APAP for 18 hours (b). Scale bar = 100 μm. 
(B) Serum iron, (C) transferrin, (D), log (ferritin), and (E) hepcidin levels are displayed as means ± SD. n highlights the amount of 
analyzed mice. **, P  < 0.01; ***, P  < 0.001.
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FIg. 2. Overview of the analyzed patients with ALF.
taBle 1. Comparison of Demographics, Clinical Characteristics, and Iron Results by alF etiology
Variable n Non-APAP (n = 55) APAP (n = 66) P Value
Age (years)* 121 46.0 (19.0) 36.0 (14.2) <0.001
Sex (% female) 121 35 (63.6) 55 (83.3) 0.024
Race (% Caucasian)† 121 35 (63.6) 59 (89.4) 0.002
Race (% African American)† 121 16 (29.1) 6 (9.1)
Race (% other)† 121 4 (7.3) 1 (1.5)
Ethnicity (% not Hispanic or Latino)† 121 48 (87.3) 64 (97.0) 0.07
21-day outcome
Spontaneous survival (% yes) 121 21 (38.2) 38 (57.6) 0.05
Admission labs
ALT (IU/L)* 119 639.0 (1,167.0) 3,549.5 (4,229.0) <0.001
AST (IU/L)* 120 533.5 (1,259.5) 4,717.0 (6,897.0) <0.001
Alkaline phosphate (IU/L)* 120 172.0 (103.8) 120.5 (56.0) <0.001
Bilirubin (mg/dL)* 120 18.0 (12.3) 4.4 (3.6) <0.001
Creatinine (mg/dL)* 121 1.0 (1.8) 1.6 (1.9) 0.008
Creatinine2 (mg/dL)‡ 121 1.1 (2.9) 2.1 (3.0) 0.02
Hemoglobin (g/dL)* 119 11.5 (3.2) 10.6 (2.9) 0.13
INR* 121 2.5 (1.4) 3.3 (2.7) 0.005
MELD* 120 30.2 (13.7) 33.7 (8.0) 0.47
Platelet count* 119 134.0 (117.5) 122.5 (120.8) 0.38
Toxin screen (% yes) 95 13 (33.3) 36 (64.3) 0.006
Venous ammonia* 76 79.5 (73.2) 103.0 (66.2) 0.09
Leucocyte count (×109/L)* 119 8.9 (5.9) 9.5 (9.3) 0.21
Peak labs
ALT peak (IU/L)* 121 697.0 (1,147.5) 4,542.5 (4,192.8) <0.001
AST peak (IU/L)* 121 566.0 (1,285.0) 5,995.0 (7,403.9) <0.001
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Variable n Non-APAP (n = 55) APAP (n = 66) P Value
Bilirubin peak (mg/dL)* 121 21.1 (9.9) 7.5 (5.9) <0.001
Creatinine peak (mg/dL)* 121 1.7 (1.9) 2.5 (2.6) 0.015
INR peak* 121 3.0 (2.3) 3.9 (2.6) 0.11
MELD peak* 121 35.4 (13.5) 35.2 (9.9) 0.61
Platelet count nadir* 121 99.0 (93.0) 70.5 (62.5) 0.012
Venous ammonia peak* 81 106.0 (84.5) 105.0 (71.2) 0.61
Admission vitals
Diastolic blood pressure (mm Hg)* 121 68.0 (21.0) 67.0 (24.5) 0.96
Systolic blood pressure (mm Hg)* 121 124.0 (18.5) 120.0 (26.5) 0.28
Weight (kg)* 117 81.5 (29.5) 73.0 (26.0) 0.06
Body mass index* 105 28.4 (7.0) 25.2 (7.9) 0.06
Clinical parameters at admission
HE grade* 121 2.0 (2.0) 3.0 (2.0) <0.001
Coma grade (% 3/4) 121 16 (29.1) 42 (63.6) <0.001
Pressors (% yes) 121 6 (10.9) 13 (19.7) 0.28
RRT (% Yes) 121 10 (18.2) 14 (21.2) 0.85
Ventilator (% yes) 121 15 (27.3) 44 (66.7) <0.001
Transfusion (before specimen day)
Pre admission FFP (% yes) 118 20 (38.5) 29 (43.9) 0.68
Pre admission to specimen day FFP (% yes) 121 31 (56.4) 48 (72.7) 0.09
Admission to specimen day RBC (% yes) 121 16 (29.1) 16 (24.2) 0.69
Admission to specimen day RVIIA (% yes)† 121 0 (0.0) 3 (4.5) 0.25
Admission to specimen day platelets (% yes) 121 9 (16.4) 13 (19.7) 0.81
Admission to specimen day Vitamin K (% yes) 121 4 (7.3) 10 (15.2) 0.29
Admission to specimen day blood product (% yes) 121 33 (60) 48 (72.7) 0.2
RRT (before specimen day)
Admission to specimen day RRT (% yes) 121 11 (20.0) 16 (24.2) 0.74
Clinical parameters during hospitalization
Peak coma grade during hospitalization* 121 2.0 (2.0) 4.0 (2.0) 0.009
Pressors during hospitalization (% yes) 121 14 (25.5) 16 (24.2) 1
RRT during hospitalization (% yes) 121 13 (23.6) 21 (31.8) 0.43
Ventilator during hospitalization (% yes) 121 22 (40.0) 52 (78.8) <0.001
Diabetes
Diabetes (% yes) 121 13 (23.6) 10 (15.2) 0.34
Transplant
Ever listed for transplant (% yes) 121 23 (41.8) 25 (37.9) 0.8
LTx within 21 days (% yes) 121 17 (30.9) 15 (22.7) 0.42
Iron indices
Ferritin (ng/mL)* 120 1,935 (4,422) 4,179 (19,482) 0.018
Iron (µmol/L)* 121 30.6 (17.4) 34.5 (25.9) 0.08
Transferrin (mg/dL)* 121 165.0 (58.5) 198.0 (81.0) 0.008
Hepcidin (ng/mL)* 113 3.3 (6.7) 6.8 (13.6) 0.008
Transferrin saturation (%)* 121 71.9 (40.7) 71.4 (32.3) 0.83
Hepcidin/ferritin ratio* 112 0.0018 (0.0063) 0.0016 (0.0079) 0.80
Data expressed as median (IQR) for continuous variables and n (%) for categorical variables.
*Presented as median (IQR) with Wilcoxon rank-sum P value.
†The P  value is calculated by the Fisher’s exact test.
‡If on renal replacement therapy at admission, creatinine set to 4.0.
Abbreviations: FFP, fresh frozen plasma; LTx, liver transplantation; RBC, red blood cells; RRT, renal replacement therapy; rVIIa, 
recombinant factor VII.
taBle 1. Continued
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taBle 2. Comparison of Demographics and Clinical Characteristics of the patient Cohort by NSS/SS Status
Variable n NSS (n = 62) SS (n = 59) P Value
Age (years)* 121 40.5 (16.8) 38.0 (21.0) 0.84
Sex (% female) 121 40 (64.5) 50 (84.7) 0.019
Race (% Caucasian)† 121 48 (77.4) 46 (78.0) 0.83
Race (% African American)† 121 12 (19.4) 10 (16.9)
Race (% other)† 121 2 (3.2) 3 (5.1)
Ethnicity (% not Hispanic or Latino)† 121 58 (93.5) 54 (91.5) 0.74
Admission labs
ALT (IU/L)* 119 1,629.5 (2,846.2) 2,333.0 (4,233.0) 0.21
AST (IU/L)* 120 1,524.0 (4,350.0) 2,043.0 (6,041.5) 0.45
Alkaline phosphate (IU/L)* 120 136.0 (83.0) 143.0 (96.0) 0.99
Bilirubin (mg/dL)* 120 10.8 (14.6) 4.9 (10.3) <0.001
Creatinine (mg/dL)* 121 1.4 (1.8) 1.2 (1.7) 0.27
Hemoglobin (g/dL)* 119 11.2 (2.9) 10.7 (2.7) 0.56
INR* 121 3.1 (2.6) 2.3 (2.2) 0.007
MELD score* 120 36.2 (11.1) 28.6 (8.9) <0.001
Platelet count* 119 92.0 (102.0) 159.5 (119.8) <0.001
Venous ammonia (µmol/L)* 76 101.0 (80.5) 90.0 (48.2) 0.49
Leucocyte count (×10 9/L)* 119 9.6 (7.6) 8.8 (7.3) 0.47
Peak labs
ALT peak (IU/L)* 121 1,629.5 (3,725.2) 2,471.0 (4,108.5) 0.2
AST peak (IU/L)* 121 1,603.5 (5,036.0) 2,319.0 (6,074.5) 0.38
Bilirubin peak (mg/dL)* 121 16.8 (15.1) 8.5 (10.5) <0.001
Creatinine peak (mg/dL)* 121 2.3 (2.0) 1.6 (2.5) 0.15
INR peak* 121 3.9 (3.1) 2.8 (2.4) <0.001
MELD score peak* 121 38.8 (8.2) 30.3 (8.5) <0.001
Platelet count nadir* 121 63.5 (53.2) 106.0 (85.5) 0.002
Venous ammonia peak (µmol/L)* 81 128.0 (90.0) 91.5 (70.8) 0.07
Etiology
APAP (% yes) 121 28 (45.2) 38 (64.4) 0.05
Admission vitals
Diastolic blood pressure (mm Hg)* 121 67.0 (24.8) 69.0 (22.0) 0.70
Systolic blood pressure (mm Hg)* 121 120.0 (24.2) 124.0 (21.0) 0.83
Weight (kg)* 117 76.9 (29.0) 77.0 (25.5) 0.82
Body mass index* 105 25.9 (8.1) 27.3 (8.9) 0.55
Clinical parameters at admission
Hepatic encephalopathy grade* 121 3.0 (2.0) 2.0 (2.0) 0.002
Coma grade (% 3/4) 121 38 (61.3) 20 (33.9) 0.005
Vasopressor use (% yes) 121 16 (25.8) 3 (5.1) 0.004
RRT (% yes) 121 17 (27.4) 7 (11.9) 0.06
Ventilation (% yes) 121 37 (59.7) 22 (37.3) 0.023
Transfusion (before specimen day)
Pre admission FFP (% yes) 118 32 (54.2) 17 (28.8) 0.009
Pre admission to specimen day FFP (% yes) 121 47 (75.8) 32 (54.2) 0.021
Admission to specimen day RBC (% yes) 121 25 (40.3) 7 (11.9) <0.001
Admission to specimen day rVIIa (% yes)† 121 3 (4.8) 0 (0.0) 0.24
Admission to specimen day platelets (% yes) 121 17 (27.4) 5 (8.5) 0.01
Admission to specimen day Vitamin K (% yes) 121 6 (9.7) 8 (13.6) 0.70
RRT (before specimen day)
Admission to specimen day RRT (% yes) 121 20 (32.3) 7 (11.9) 0.013
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(Table 1 and in Materials and Methods). Although 
the reference range for hepcidin remains to be defined, 
the detected values tended to be lower than the ones 
obtained previously in healthy population controls.(24) 
With regard to ALF etiology, subjects with APAP-
induced ALF had higher transferrin (198.0 (81.0) vs. 
165.0 (58.5) mg/dL; P  < 0.01), hepcidin (6.8 (13.6) vs. 
3.3 (6.7) ng/mL; P  < 0.01), and ferritin levels (4,179.0 
(19,481.7) vs. 1,935.0 (4,421.8) ng/mL; P  < 0.05) 
than non-APAP cases (Table 1).
Compared with NSS, SS displayed significantly 
lower TSAT levels (60.9% (47.2)% vs. 79.1% (21.1)%; 
P  < 0.01) and lower levels of serum iron (29.1 (22.1) 
vs. 34.5 (20.6) µmol/L; P  < 0.05), but had higher hep-
cidin values (8.2 (14.2) vs. 2.7 (5.9) ng/mL; P  < 0.001) 
and hepcidin/ferritin ratios (0.0047 (0.0219) vs. 
0.0009 (0.0029); P  < 0.0001; Table 2). In this sample, 
ferritin levels were similar among SS and NSS groups 
(2,925 (13,716) vs. 2,755 (10,018) ng/mL; P = 0.058), 
and no differences in the pattern of association by sex 
were observed. Although the average serum iron and 
hepcidin levels differed somewhat between APAP and 
non-APAP cases (Table 1), the above-described dif-
ferences between SS and NSS with regard to serum 
iron, TSAT, hepcidin, and hepcidin/ferritin ratios 
were concordant in both subgroups (Fig. 3).
Among the iron parameters, hepcidin/ferritin ratio 
correlated negatively with iron (r = −0.47; P  < 0.001) 
and TSAT (r = −0.63; P  < 0.001), whereas TSAT 
and ferritin displayed a positive correlation (r = 0.59; 
P  < 0.001). Hepcidin/ferritin ratio also exhibited a 
weak negative correlation with parameters of a liver 
injury/dysfunction such as AST (r = −0.37; P  < 0.001), 
MELD (r = −0.32; P  < 0.001), and INR (r = −0.51; 
P  < 0.001), and a similar association was noted 
between hepcidin and bilirubin (r = −0.30; P  < 0.001). 
Along the same lines, the ALFSG prognostic index 
positively correlated with both hepcidin (r = 0.51, 
P  < 0.001) and hepcidin/ferritin ratio (r = 0.33, 
P  < 0.001; for details, see Supporting Table S6).
HepCIDIN CoNStItUteS aN 
INDepeNDeNt pReDICtoR 
oF 21-Day tRaNSplaNt-FRee 
SURVIVal
To evaluate the prognostic significance of iron 
parameters for 21-day SS, we performed univariate 
logistic regression. It revealed a significant predictive 
value for iron (P  < 0.05), TSAT (P  < 0.01), logarith-
mic transformed (hepcidin+1; P  < 0.001) and square-
root transformed hepcidin/ferritin ratio (P  < 0.001) 
Variable n NSS (n = 62) SS (n = 59) P Value
Clinical parameters during hospitalization
Coma grade during hospitalization* 121 4.0 (1.0) 2.0 (3.0) <0.001
Vasopressor use during hospitalization (% yes) 121 25 (40.3) 5 (8.5) <0.001
RRT during hospitalization (% yes) 121 22 (35.5) 12 (20.3) 0.1
Ventilation during hospitalization (% yes) 121 48 (77.4) 26 (44.1) <0.001
Transplant
Ever listed for transplant (% yes) 121 39 (62.9) 9 (15.3) <0.001
Iron indices
Ferritin (ng/mL)* 120 2,755 (10,018) 2,925 (13,716) 0.58
Iron (µmol/L)* 121 34.5 (20.6) 29.1 (22.3) 0.016
Transferrin (mg/dL)* 121 172.5 (80.2) 186.0 (79.5) 0.34
Hepcidin (ng/mL)* 113 2.7 (5.9) 8.2 (14.2) <0.001
Transferrin saturation (%)* 121 79.1 (21.1) 60.9 (47.2) 0.001
Hepcidin/ferritin ratio* 112 0.0009 (0.0029) 0.0047 (0.0219) <0.001
Data expressed as median (IQR) for continuous variables and n (%) for categorical variables.
*Presented as median (IQR) with Wilcoxon rank sum P value.
†The P value is calculated by the Fisher’s exact test.
Abbreviations: FFP, fresh frozen plasma; RBC, red blood cells; RRT, renal replacement therapy; rVIIa, recombinant factor VII.
taBle 2. Continued
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(Table 3). We also conducted multivariate analysis 
including all potentially relevant markers. Log (INR; 
P  < 0.05), coma grade 3/4 (P  < 0.001), platelet count 
(P  < 0.001), APAP etiology (P  < 0.01), and log (hep-
cidin+1; P  < 0.05) were found as the only parame-
ters that independently associated with 21-day SS 
(Table 3). To determine the potential usefulness of 
log (hepcidin+1) in the clinical routine, we investi-
gated whether its combination with other established 
markers improves the currently used outcome indices, 
i.e., the MELD and the ALFSG model.(6) Forward-
selection procedures identified a combination of 
platelet count, log (INR), APAP etiology, coma grade 
(3/4), and log (hepcidin+1) as the most parsimonious 
and best predictive score (Table 4). Compared with 
both the MELD and ALFSG models, it achieved the 
highest sensitivity (81%) and specificity (79.6%), and 
the performance of this model was good as defined by 
the area under the curve (AUC 0.87; 95% confidence 
interval [CI] 0.80-0.93) (Table 4, Fig. 4). In contrast, 
FIg. 3. Parameters of iron metabolism in patients with ALF grouped by etiology and survival status. (A) Log (ferritin), (B) iron, 
(C) log (hepcidin+1), (D) hepcidin/ferritin ratio, and (E) transferrin levels as well as (F) TSAT were determined in the highlighted 
subgroups of patients with ALF. Boxplots display median with first and third quartile, and whiskers indicate smallest and largest 
nonoutlier observations. Outliers are depicted by empty circles. APAP/non-APAP refers to the ALF etiology (acetaminophen-related 
or not). Non-SS are individuals who, in contrast with spontaneous survivals (SS), either died or required a liver transplantation within 
3 weeks of enrollment. *, P  < 0.05; ***, P  < 0.001.
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the MELD and ALFSG models reached an AUC 
(95% CI) of 0.76 (0.67-0.85) and 0.85 (0.78-0.92), 
respectively (Table 4; Fig. 4).
Discussion
Our study demonstrated that patients with ALF 
display markedly altered iron parameters. However, 
the observed changes clearly differed from the alter-
ations seen in other liver disorders. In line with 
a previous report, we saw a massive increase in 
serum ferritin that surpassed the levels detected in 
other diseases such as compensated liver cirrhosis, 
acute-on-chronic liver failure, or sepsis.(11,18,19,21,24) 
The rise in ferritin was recapitulated in our exper-
imental ALF model and is not surprising because 
ferritin is present in large amounts in hepatocytes 
and is released into serum during liver injury.(25) 
Accordingly, we observed a strong correlation 
between serum ferritin and the serum liver enzyme 
levels. Consequently, the high ferritin levels mirror 
the acute, massive liver damage characteristic for 
ALF.
Our study and the work from Anastasiou et al.(11) 
reported very similar levels of serum iron and 
taBle 3. Univariate and Multivariable logistic Regression 
analysis for 21-Day Spontaneous Survival
Variable
Univariate  
(n = 121)
Multivariate 
(n = 121)
Estimate P Value Estimate P Value
Bilirubin (mg/dL) 0.07015 0.002
Creatinine2 (mg/dL)* 0.20672 0.07
Log (INR) 1.00832 0.009 1.4888 0.012
MELD 0.13839 <0.001
Platelet count −0.00797 0.002 −0.0111 <0.001
Height (cm) 0.03276 0.09
Iron (µmol/L) 0.02723 0.013
Transferrin saturation (%) 0.01979 0.004
Log (hepcidin+1) (ng/mL) −0.83198 <0.001 −0.7257 0.01
Square root (hepcidin/ferritin) −14.8873 <0.001
APAP (yes) −0.39361 0.035 −2.2672 0.002
Sex (female) −0.55848 0.013
Vasopressors (yes) 0.93522 0.005
RRT (yes) 0.51594 0.037
Ventilation (yes) 0.45595 0.015
Coma grade (3/4) 0.56364 0.003 2.4221 <0.001
Blood product (yes) 0.49684 0.013
Before specimen day RRT (yes) 0.63170 0.009
Probability of death or transplant within 21 days is modeled.
*If on renal replacement therapy at admission, creatinine set to 
4.0.
Abbreviation: RRT, renal replacement therapy.
taBle 4. Iron, MelD, and alFSg prognosis Model Results
MELD Model ALFSG Model Iron Model
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
MELD 1.15 (1.1-1.22) <0.001 — — — —
Favorable etiology (yes)* — — 0.4 (0.08-1.91) 0.25 — —
APAP etiology (yes) — — — — 0.10 (0.02-0.45) 0.002
Log (INR) — — 6.96 (2.24-21.59) <0.001 4.43 (1.38-14.23) 0.012
Log (bilirubin) — — 3.69 (1.6-8.75) 0.003 — —
Platelet count — — — — 0.99 (0.98-1) <0.001
Log (hepcidin+1) — — — — 0.48 (0.28-0.84) 0.01
Coma grade (3/4) — — 7.61 (2.13-27.21) 0.002 11.27 (2.91-42.8) <0.001
Vasopressors (yes) — — 3.02 (0.64-14.3) 0.16 — —
Sensitivity (%) 65.6 73.8 81.0
Specificity (%) 69.5 69.5 79.6
C-statistic (95% CI) 0.76 (0.67-0.85) 0.85 (0.78-0.92) 0.87 (0.81-0.94)
The sensitivity and specificity is based on a cut-point of 0.50.
*Favorable etiologies: acetaminophen-induced ALF, hepatitis A, pregnancy-related ALF, ischemic liver injury.
Abbreviations: CI, confidence interval; OR, odds ratio.
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transferrin. Serum iron exceeded the values seen in 
decompensated liver cirrhosis, acute-on-chronic liver 
failure, and severe alcoholic hepatitis (unpublished 
data; also see a previous work(19)). Moreover, the 
experimental model demonstrated that the increased 
serum iron levels constitute a late event during APAP 
toxicity. These high levels likely reflect the large cell 
turnover and the diminished hepcidin production.(12) 
Moreover, the transferrin levels observed in both 
human studies and the experimental ALF model were 
above the values detected in individuals with sepsis or 
decompensated liver cirrhosis.(19,24) These fairly pre-
served transferrin levels are likely due to the rather 
long serum half-life of transferrin (8-10 days)(26) and 
the lack of inflammation that suppresses transferrin 
production.(24,27)
Because of the high serum iron levels, subjects with 
ALF exhibited TSAT values that were above the ones 
seen in decompensated cirrhosis or acute-on-chronic 
liver failure.(18,19,22) These data indicate that ALF 
leads to a breakdown of the serum iron metabolism. 
This is not surprising because serum iron represents 
a very small and dynamic fraction of the total iron 
body stores that is altered in multiple human disor-
ders.(18,19,24) In particular, the serum iron overload is 
likely facilitated by decreased iron consumption that 
is common in critically ill patients(28) as well as by an 
increased release of iron from damaged cells and red 
blood cell transfusions.
Even more interestingly, TSAT levels were signifi-
cantly elevated in NSS individuals compared with 
survivors. Although a causal impact of elevated TSAT 
on ALF development remains to be proved, several 
mechanisms might play a role. First, increased TSAT 
leads to generation of the highly reactive non–trans-
ferrin-bound iron that is known to cause oxidative 
stress and endothelial damage.(29,30) Moreover, higher 
iron availability might be exploited by microorganisms 
FIg. 4. Diagnostic accuracy of selected models to predict 21-days spontaneous survival in patients with acute liver failure. ROC curves 
are shown for the MELD, ALFSG (consisting of ALF etiology, need for vasopressor therapy, INR, bilirubin, and coma grade ≥3), 
and iron model (consisting of log [hepcidin+1], platelet count, log [INR], ALF etiology, and coma grade ≥3). AUCs are indicated as 
C-statistic. Abbreviation: ROC, receiver operating characteristics.
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and thereby predispose to development of microbial 
infections.(12) Although microbial infection and oxi-
dative stress are of great importance in ALF,(31,32) 
they also play a crucial role in multiple other disor-
ders. In that respect, high TSAT has been shown to 
constitute a negative outcome predictor in critically ill 
patients, individuals with decompensated liver cirrho-
sis or acute lymphocytic leukemia.(18,19,24,33)
Compared with healthy subjects,(24) individuals 
with ALF displayed decreased hepcidin levels. This 
is not surprising because diminished hepcidin was 
reported in patients with impaired liver function.(34,35) 
In line, our experimental ALF model revealed a strong 
negative correlation between serum hepcidin levels 
and the markers of liver injury, and similar, albeit less 
pronounced, correlation was observed in patients with 
ALF. In addition to that, hypoxia, the serum iron over-
load, and oxidative stress are further factors commonly 
seen in patients with ALF that are known to suppress 
hepcidin production.(12,34) Although hepcidin is a 
well-known acute phase reactant, the above-described 
suppressive factors were obviously more potent than 
the potential inducers.
Hepcidin levels were particularly low in NSS, 
and hepcidin constituted an independent predictor 
of ALF-related survival. These data are reminiscent 
of the situation in compensated cirrhosis, in which 
low hepcidin levels were also associated with a poor 
survival.(22) In contrast, hepcidin did not predict sur-
vival in cohorts with a significant amount of micro-
bial infections, including critically ill patients and 
individuals with acute-on-chronic liver injury.(19,24) 
Collectively, these observations suggest that in absence 
of inflammation or in a situation in which other fac-
tors outweigh the existing inflammation, hepcidin may 
serve as a marker of liver function; however, hepcidin 
also provides added benefits, as demonstrated in the 
multivariate analysis. Notably, in comparison with the 
established liver function parameters such as albumin 
or INR, hepcidin has a much shorter half-life,(36) and 
the hepcidin changes in the experimental ALF model 
occurred at an early time point after APAP expo-
sure. Thus, hepcidin might better reflect the dynamic 
changes occurring in ALF. In contrast, transferrin 
might be the better predictor in disorders associated 
with a more pronounced inflammation.(18,19,24)
As a possibility to enhance the prognostic useful-
ness of hepcidin, we analyzed hepcidin/ferritin ratio. 
Although serum hepcidin and ferritin significantly 
correlate in healthy subjects,(37) this relationship is 
altered in advanced liver disease(34) and even more in 
ALF, which displays low hepcidin but strongly ele-
vated ferritin as a surrogate of the hepatocellular injury 
(our study; also see previous works(11,25)). Although 
hepcidin/ferritin ratio greatly differed between ALF 
survivors and NSS, multivariate analysis revealed that 
it may not provide a better predictive value than hep-
cidin alone.
In conclusion, our study detected unique alter-
ations in iron parameters in individuals with ALF and 
demonstrated that they may serve as useful predictors 
of disease outcome. Although they seem to primarily 
serve as surrogates for the extent of liver injury and 
decreased liver function, they may also play a causal 
role in ALF development. Further studies are needed 
to explore this intriguing possibility as well as to 
address the usefulness of iron parameters in different 
ALF etiologies.
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